Plain-English translation of NCT05957250 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new imaging scan called [68Ga]Ga-FAPI-46 PET that is designed to better detect pancreatic and bile duct cancers in the body. Unlike standard imaging, this new scan uses a special tracer that targets cancer cells more accurately, which may help doctors find small tumors and tell the difference between cancer and healthy tissue. The study has three parts: first checking how the medication works in your body, then testing if it gives the same results when repeated, and finally seeing if it can track how well treatment is working.
Pancreatic and bile duct cancers are very serious, and doctors need better tools to find them early and decide the best treatment plan. Current imaging methods often miss small tumors or cannot tell whether remaining tissue after treatment is cancer or scar tissue. This medication may solve that problem by lighting up cancer cells so doctors can see them more clearly.
Depending on which part of the study you join, you will receive one or two injections of the new tracer medication and undergo PET/CT imaging scans (imaging that takes pictures of your body). In the first part, researchers will also place a small tube in an artery to monitor how your body handles the medication. The study may take place over a few weeks or longer, with repeat scans depending on your part. Your doctor will explain the specific timing and number of visits when you enroll.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Netherlands